Patients with CRC previously received cytotoxic chemotherapy (99.2%), anti-VEGF biologics (93.7%), or anti-EGFR biologics (34.7%) as prior treatments, while majority of patients with HCC and all patients with GIST received tyrosine kinase inhibitors (Table S1). The gene discussed is EGFR; the disease is gastrointestinal stromal tumor.